{
  "id": "cluster_6_doc1",
  "content": "A 42-year-old individual with recessive dystrophic epidermolysis bullosa underwent gene therapy at Pinnacle Genomics Institute under policy SBT-449Q. The treatment required prior authorization due to experimental status. Final approval came through on 03/15/2023 after appeals process. Clinical notes indicate compassionate use protocol adherence.",
  "metadata": {
    "format": "medical_record"
  }
}